Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The investigators objective is to test the combination directly on organotypic cultures of
tumors from patients after their excision in the Department of Urology and Renal
Transplantation of the University Hospital of Grenoble and to compare their efficacy with
that of currently selected treatments in the clinic.
The population targeted by the combination for use in clinical practice is patients with
metastatic clear cell renal cell carcinoma.
Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Grenoble
Treatments:
Everolimus Protein Kinase Inhibitors Sirolimus Sunitinib